- Home
- SVMH vs ZVSA Comparison
SVMH vs ZVSA Comparison
Compare SVMH & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVMH
- ZVSA
- Stock Information
- Founded
- SVMH 2018
- ZVSA 2014
- Country
- SVMH Cayman Islands
- ZVSA United States
- Employees
- SVMH N/A
- ZVSA N/A
- Industry
- SVMH
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- SVMH
- ZVSA Health Care
- Exchange
- SVMH Nasdaq
- ZVSA Nasdaq
- Market Cap
- SVMH 3.1M
- ZVSA 2.5M
- IPO Year
- SVMH N/A
- ZVSA N/A
- Fundamental
- Price
- SVMH $0.03
- ZVSA $1.10
- Analyst Decision
- SVMH
- ZVSA Strong Buy
- Analyst Count
- SVMH 0
- ZVSA 1
- Target Price
- SVMH N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- SVMH 108.1M
- ZVSA 243.8K
- Earning Date
- SVMH 12-31-2024
- ZVSA 11-14-2024
- Dividend Yield
- SVMH N/A
- ZVSA N/A
- EPS Growth
- SVMH N/A
- ZVSA N/A
- EPS
- SVMH N/A
- ZVSA N/A
- Revenue
- SVMH $42,538.00
- ZVSA N/A
- Revenue This Year
- SVMH N/A
- ZVSA N/A
- Revenue Next Year
- SVMH N/A
- ZVSA N/A
- P/E Ratio
- SVMH N/A
- ZVSA N/A
- Revenue Growth
- SVMH N/A
- ZVSA N/A
- 52 Week Low
- SVMH $0.02
- ZVSA $0.98
- 52 Week High
- SVMH $0.48
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- SVMH 47.14
- ZVSA 41.83
- Support Level
- SVMH $0.03
- ZVSA $0.99
- Resistance Level
- SVMH $0.03
- ZVSA $1.20
- Average True Range (ATR)
- SVMH 0.01
- ZVSA 0.08
- MACD
- SVMH 0.00
- ZVSA 0.04
- Stochastic Oscillator
- SVMH 31.85
- ZVSA 54.55
About SVMH SRIVARU Holding Limited
SRIVARU Holding Ltd focuses to revolutionize two-wheeled vehicles (TWV) by developing products powered by renewable energy, which are assured for safety, performance, and comfort, thereby providing safe riding experience to its customers. It operates in one reportable segment which is vehicle manufacturing. SVH's first product line, the Prana, is a E2W vehicle that is redefining the category. SVH has commenced engineering and design work for the Prana-Elite that is expected to leverage the same platform as the Prana-Grand, while upgrading its range.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.